Winona HRT: Specific Patient Profiles to Avoid and Who Should Look Elsewhere

What Is Winona and How Does Its Model Work

Winona is an online-only, cash-pay menopause telehealth company that connects patients with state-licensed physicians to prescribe hormone therapy. Intake happens through an online questionnaire; follow-up visits are asynchronous or via video. Medications are compounded by third-party pharmacies and shipped directly to patients.

The compounding pharmacy issue

Winona relies heavily on compounded hormone preparations. The FDA has stated clearly that compounded drugs "lack FDA approval" and have "not been shown to be safe or effective" under the same standards applied to commercially manufactured products. The agency's 2008 and 2020 guidance documents on compounded hormone therapy are available at FDA.gov [1]. This does not make compounded hormones automatically dangerous, but it does mean patients receive formulations without the same clinical-trial evidence base as brand-name or generic FDA-approved products.

Asynchronous care and its limits

Because much of the intake is questionnaire-based, Winona prescribers do not perform physical exams, do not review imaging, and in many cases do not see baseline lab work before prescribing. The North American Menopause Society (NAMS) 2022 Position Statement recommends individualized risk assessment before initiating hormone therapy, including blood pressure measurement, breast exam documentation, and review of personal and family cancer history [2]. An asynchronous questionnaire cannot replace that assessment for patients with complex histories.

Absolute Contraindications: Women Who Should Never Use Winona

Several clinical situations make any telehealth HRT platform inappropriate. These are absolute contraindications recognized by NAMS, the American College of Obstetricians and Gynecologists (ACOG), and the FDA labeling for estrogen-containing products.

Hormone-sensitive cancers

Women with a current or prior diagnosis of estrogen-receptor-positive (ER+) breast cancer, endometrial cancer, or other hormone-sensitive malignancies should not use systemic estrogen therapy through any platform. ACOG Practice Bulletin No. 141 states that systemic hormone therapy is contraindicated in women with a history of breast cancer [3]. Telehealth intake forms, even detailed ones, cannot substitute for oncology coordination. Winona's own consent materials acknowledge this exclusion, but a questionnaire-only intake process carries a real risk of undisclosed or minimized history slipping through.

Active or recent thromboembolic disease

Oral estrogen increases the risk of venous thromboembolism (VTE). The Women's Health Initiative (WHI) randomized trial (N=16,608) found that combined conjugated equine estrogen plus medroxyprogesterone acetate increased VTE risk roughly two-fold compared with placebo (hazard ratio 2.06, 95% CI 1.57 to 2.70) [4]. Women with active deep vein thrombosis, pulmonary embolism, or a recent (within 12 months) thromboembolic event should not receive systemic estrogen. Transdermal routes carry lower VTE risk than oral routes, but the telehealth setting still cannot monitor coagulation status adequately for this group.

Unexplained vaginal bleeding

Undiagnosed abnormal uterine bleeding requires endometrial biopsy or transvaginal ultrasound before hormone therapy is initiated. No telehealth platform can order or interpret that imaging. ACOG recommends ruling out endometrial pathology before starting estrogen in women with unexplained bleeding [3]. Winona's questionnaire asks about bleeding, but an affirmative answer should route a patient to in-person evaluation, and there is no guarantee the asynchronous workflow enforces this consistently.

Active liver disease

Estrogen is metabolized hepatically. FDA labeling for all systemic estrogen products lists active liver disease or hepatic impairment as a contraindication [5]. Women with cirrhosis, active hepatitis, or cholestatic jaundice fall outside the scope of safe telehealth prescribing.

Relative Contraindications: High-Risk Profiles That Need Extra Scrutiny

Beyond absolute contraindications, several patient profiles carry enough risk that Winona's asynchronous model is likely insufficient, even if it is not strictly prohibited.

Strong family history of breast cancer or BRCA1/BRCA2 carriers

The relationship between exogenous hormone therapy and breast cancer risk is well-characterized. The Collaborative Group on Hormonal Factors in Breast Cancer meta-analysis (N=108,647 breast cancer cases) found that current use of combined estrogen-progestogen therapy for five or more years increases relative breast cancer risk by approximately 1.60 compared with never-users [6]. Women who are BRCA1 or BRCA2 carriers, or who have multiple first-degree relatives with breast cancer, need genetic counseling and oncology input before starting HRT. Winona does not offer genetic counseling.

Uncontrolled hypertension

Oral estrogen can raise blood pressure in susceptible individuals, and hypertension itself is an independent cardiovascular risk factor. The American Heart Association's 2022 guideline on menopausal hormone therapy notes that blood pressure should be controlled before initiating oral estrogen and monitored during therapy [7]. Without in-person measurement or a connected remote monitoring device, Winona cannot verify baseline or follow-up blood pressure with the same rigor as an in-person practice.

Migraine with aura

Women with migraine with aura have an approximately two-fold increased risk of ischemic stroke compared with migraine-free women, based on data published in the British Medical Journal [8]. Adding exogenous estrogen, particularly oral estrogen, may compound this risk. The clinical approach in this population typically involves low-dose transdermal estrogen with careful neurological follow-up, a nuance that asynchronous questionnaire-based prescribing is poorly equipped to manage.

Cardiovascular disease history

The WHI also showed that combined HRT initiated more than 10 years after menopause, or in women over age 60 at initiation, was associated with a statistically significant increase in coronary heart disease events [4]. NAMS frames this as the "timing hypothesis": hormone therapy started within 10 years of menopause onset or before age 60 is generally considered safe for healthy women, while initiation outside that window carries different risk calculus [2]. Winona's questionnaire asks about age of menopause onset, but verifying the 10-year window and assessing underlying subclinical cardiovascular disease requires more than self-report.

Is Winona Legit? Regulatory and Credentialing Review

This is the most-asked consumer question about the platform. The honest answer is nuanced.

Prescriber licensing

Winona's prescribers are licensed physicians in the states where they practice. State medical board databases are public records, and any patient can verify licensure at their state's medical board website. Prescribing telehealth HRT is legal in all 50 states when the prescriber holds a valid license in the patient's state of residence. On that narrow question, Winona is operating within the law.

Compounding pharmacy status

The compounding pharmacies Winona uses are required to be licensed under either 503A (patient-specific) or 503B (outsourcing facility) status. 503B facilities are subject to FDA inspection and Current Good Manufacturing Practice (CGMP) standards. The FDA maintains a list of registered 503B outsourcing facilities at FDA.gov [5]. Patients should ask Winona directly which pharmacy fulfills their prescription and verify that pharmacy's registration status independently.

BBB and LegitScript status

As of January 2025, Winona is not accredited by the Better Business Bureau and is not LegitScript-certified. LegitScript certification requires a telehealth pharmacy to meet specific standards for prescription practices, pharmacy sourcing, and patient safety protocols. The absence of LegitScript certification is not illegal, but it does remove a layer of third-party verification that platforms like Hims and Hers, for example, carry. BBB complaints filed against Winona center on billing disputes and difficulty canceling subscriptions, consistent with patterns common to subscription telehealth models generally.

The Winona Risk-Stratification Framework for Clinicians and Patients

The table below summarizes which patient profiles are appropriate, marginal, or inappropriate for Winona's asynchronous telehealth model, based on NAMS 2022 criteria [2], ACOG guidance [3], and FDA labeling [5].

| Patient Profile | Winona Appropriateness | Recommended Alternative | |---|---|---| | Healthy perimenopausal woman, age 45 to 60, no significant history | Appropriate | None needed | | ER+ breast cancer survivor | Contraindicated | Oncology-coordinated menopause specialist | | Active DVT or PE | Contraindicated | Hematology plus in-person OB/GYN | | Unexplained vaginal bleeding | Contraindicated until evaluated | In-person gynecologist | | Active liver disease | Contraindicated | Hepatology plus endocrinology | | Migraine with aura | Marginal; transdermal-only, close monitoring needed | NAMS-certified provider | | BRCA1/BRCA2 carrier | Marginal; genetics counseling required first | Genetic counselor plus oncologist | | Hypertension, uncontrolled | Marginal; BP must be controlled first | Primary care or cardiologist | | Age <40 (premature ovarian insufficiency) | Marginal; needs specialist diagnosis | Reproductive endocrinologist | | Strong family history of breast cancer | Marginal; individualized risk discussion required | NAMS-certified provider |

Winona Complaints: What Patients Actually Report

Consumer complaints about Winona cluster into a few recurring themes that are clinically relevant rather than just customer-service frustrations.

Difficulty stopping prescriptions and billing

Multiple BBB complaints describe patients who stopped feeling well on their prescribed regimen but had difficulty getting their protocol adjusted quickly through the asynchronous messaging system. For a symptom-driven therapy like HRT, where dose titration and progestogen type matter for both symptom control and safety, a slow asynchronous feedback loop is a genuine clinical limitation, not just a convenience complaint.

Lab work not required at baseline

Several patient accounts describe receiving a prescription with no baseline hormone panel, no thyroid screening, and no metabolic labs. NAMS recommends that baseline assessment include a review of relevant personal and family medical history and, where indicated, laboratory evaluation [2]. Skipping labs is not always wrong for low-risk women, but patients with symptoms that could reflect thyroid disease, adrenal dysfunction, or PCOS may receive estrogen when the underlying diagnosis is something else entirely.

Generic progesterone versus compounded options

Some patients report being switched between compounded progesterone and FDA-approved oral micronized progesterone (Prometrium) without clear explanation of the clinical rationale. This matters because FDA-approved oral micronized progesterone has a published safety and efficacy record, while compounded progesterone formulations do not carry equivalent evidence. The FDA's guidance on this distinction is explicit [1].

When to Choose a Different Platform or In-Person Care

Winona works best for a narrow but real population: healthy women between roughly 45 and 60, with low cardiovascular risk, no cancer history, no active clotting disorder, normal liver function, and menopause symptoms that are clearly attributable to estrogen deficiency. Outside that profile, the asynchronous model introduces risk.

Premature ovarian insufficiency requires specialist care

Women under age 40 with ovarian insufficiency need a formal diagnosis confirmed by two fasting FSH measurements taken at least four weeks apart, as recommended in the European Society of Human Reproduction and Embryology (ESHRE) 2016 guideline [9]. A questionnaire cannot confirm this diagnosis. These patients also need bone density monitoring (DEXA), which Winona cannot arrange.

Post-cancer hormone therapy is a specialist conversation

Women who have completed treatment for ER-negative breast cancer sometimes ask about hormone therapy for menopausal symptoms. Even in that relatively lower-risk scenario, the decision requires an oncologist's input, documented shared decision-making, and a specific monitoring plan, none of which a telehealth platform is equipped to provide.

Finding a NAMS-certified menopause specialist

The North American Menopause Society maintains a searchable directory of certified menopause practitioners at menopause.org [10]. Women who fall into any of the marginal or contraindicated categories above should use that directory to find a credentialed specialist rather than a cash-pay telehealth platform.

What Winona Does Well (for the Right Patient)

An independent review requires fairness. For the correctly selected patient, Winona removes several real barriers to menopause care. Fewer than 20% of OB/GYN residency programs provide comprehensive menopause training, according to a 2019 survey published in Menopause [11]. Many women wait 18 months or more for a specialist appointment. For a low-risk woman in a rural area whose primary care provider is uncomfortable prescribing HRT, Winona may provide faster access to a treatment that has proven symptom benefit.

The NAMS 2022 Position Statement concludes that "for women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [2]. Winona's target patient is exactly that woman.

The problem is that Winona's intake process does not reliably filter out women who do not meet those criteria. Patients bear significant responsibility for accurate self-reporting, and the platform bears responsibility for building clinical decision-support workflows strong enough to catch the exceptions.